IP Library › Granted Patent US 8,637,004
Granted Patent B2
US 8,637,004 · App. 12/541,282 · Granted Jan 28, 2014

Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,637,004
App. No.
12/541,282
Granted
Jan 28, 2014
Kind
B2
Abstract

One or more purified mesenchymal stem cell pharmaceutical compositions and methods of manufacture utilizing centrifugal filtration are disclosed. Threshold limits for intravenous administration of mesenchymal stem cell pharmaceutical compositions comprising residual animal products are also disclosed.

Claims (15)

1. A pharmaceutically acceptable composition comprising purified mesenchymal stem cells, wherein the composition comprises one or more mesenchymal stem cell aggregates and wherein the diameter which is greater than 90% or more of said aggregates (D 90 ) is less than about 150 μm.

2. The pharmaceutically acceptable composition of claim 1 , wherein the D 90 of said aggregates is less than about 100 μm.

3. The pharmaceutically acceptable composition of claim 2 , wherein the D 90 of said aggregates is less than about 50 μm.

4. The pharmaceutically acceptable composition of claim 1 , wherein the portion of the purified mesenchymal stem cells which are viable is greater than about 70%.

5. The pharmaceutically acceptable composition of claim 4 , wherein the portion of the purified mesenchymal stem cells which are viable is greater than about 80%.

6. A pharmaceutically acceptable composition comprising purified mesenchymal stem cells, wherein the composition comprises less than about 55 μg/mL bovine serum albumin and wherein the composition comprises one or more mesenchymal stem cell aggregates and wherein the diameter which is greater than 90% of said aggregates (D 90 ) is between about 18 μm and about 30 μm.

7. The composition of claim 6 , wherein the composition comprises less than about 42 μg/mL bovine serum albumin.

8. The composition of claim 7 , wherein the composition comprises less than about 25 μg/mL bovine serum albumin.

9. The composition of claim 8 , wherein the composition comprises less than about 13 μg/mL bovine serum albumin.

10. The composition of claim 9 , wherein the composition comprises less than about 10 μg/mL bovine serum albumin.

11. The composition of claim 6 , wherein the composition comprises between about 7 μg/mL and about 15 μg/mL bovine serum albumin.

12. The composition of claim 11 , wherein the composition comprises between about 8 μg/mL and about 12 μg/mL bovine serum albumin.

13. The composition of claim 6 , wherein the D 90 is between about 18 μm and about 25 μm.

14. The composition of claim 6 , wherein the portion of the purified mesenchymal stem cells which are viable is greater than about 70%.

15. The composition of claim 14 , wherein the portion of the purified mesenchymal stem cells which are viable is greater than about 80%.

Assignments (8)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jan 2, 2026
From: OAKTREE FUND ADMINISTRATION, LLC, AS AGENT
To: MESOBLAST LIMITED; MESOBLAST UK LIMITED; MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.); MESOBLAST INTERNATIONAL SÀRL
Reel/Frame 074174/0183 →
RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT AT REEL/FRAME NO. 45759/0917 Recorded Jul 30, 2025
From: HERCULES CAPITAL, INC., AS AGENT
To: MESOBLAST INTERNATIONAL SARL
Reel/Frame 072297/0753 →
SECURITY INTEREST Recorded Dec 10, 2021
From: MESOBLAST LIMITED ACN 109 431 870; MESOBLAST UK LIMITED; MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.); MESOBLAST INTERNATIONAL SÀRL
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 058957/0447 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 10, 2018
From: MESOBLAST INTERNATIONAL SARL
To: NQP SPV II, L.P., AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
Reel/Frame 046515/0222 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Mar 28, 2018
From: MESOBLAST INTERNATIONAL SARL
To: HERCULES CAPITAL, INC., AS ADMINISTRATIVE AND COLLATERAL AGENT
Reel/Frame 045759/0917 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 1, 2013
From: OSIRIS THERAPEUTICS, INC.
To: MESOBLAST INTERNATIONAL SÀRL
Reel/Frame 031533/0828 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2009
From: TON, CHRISTOPHER
To: OSIRIS THERAPEUTICS, INC.
Reel/Frame 023336/0578 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2009
From: DANILKOVICH, ALLA; NEWMAN, ROBERT E., JR.; TOM, SAMSON; TON, CHRISTOPHER; WANG, ZHANLING; YOUNG, RANDELL G.
To: OSIRIS THERAPEUTICS, INC.
Reel/Frame 023283/0592 →